Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
ZBP is a biopharmaceutical company that has developed a proprietary technology to ...
ZBP is a biopharmaceutical company that has dev...
NuVasive is a world leader in minimally invasive, procedurally integrated spine so...
NuVasive is a world leader in minimally invasiv...
Compugen is a drug discovery company with a unique, broadly applicable, predictive...
Compugen is a drug discovery company with a uni...
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unl...
Selecta Biosciences, Inc. is a clinical-stage b...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, incl...
Harrow Health, Inc. (NASDAQ: HROW) owns a portf...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused...
TRACON Pharmaceuticals, Inc. is a clinical stag...
Join the National Investor Network and get the latest information with your interests in mind.